397 related articles for article (PubMed ID: 29190182)
21. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
22. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
23. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T; Mihalyova J; Kascak M; Duras J; Hajek R
Immunology; 2017 Nov; 152(3):357-371. PubMed ID: 28685821
[TBL] [Abstract][Full Text] [Related]
24. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
25. Managing adverse effects of immunotherapy.
Gerson JN; Ramamurthy C; Borghaei H
Clin Adv Hematol Oncol; 2018 May; 16(5):364-374. PubMed ID: 29851932
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
27. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Graziani G; Lisi L; Tentori L; Navarra P
Exp Suppl; 2022; 113():295-350. PubMed ID: 35165868
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
31. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
32. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn RE; Hamid O; de Vries EG; Ott PA; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Cho DC; Plummer R; Stroh M; Lu L; Thistlethwaite F
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301808
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
35. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
36. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
39. Programmed cell death protein receptor and ligands in haematological malignancies - Current status.
Sokołowski M; Sokołowska A; Mazur G; Butrym A
Crit Rev Oncol Hematol; 2019 Mar; 135():47-58. PubMed ID: 30819446
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
